Acute Porphyria Drug Database

J07BG01 - Rabies, Inactivated, Whole Virus
Propably not porphyrinogenic
PNP

Rationale
Based on the pharmacokinetics of the rabies, inactivated, whole virus vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Inactivated rabies virus.
Therapeutic characteristics
The rabies vaccine is indicated for pre-exposure and post-exposure prophylaxis against rabies. It is administered intramuscular according to a three or five dose schedule.
Metabolism and pharmakokinetics
The rabies vaccine is not metabolized by the cytochrome P450 system.
IPNet drug reports
Uneventful use reported in 2 patients with acute porphyria.

References

  1. Government bodies
  2. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
  3. Summary of Product Characteristics
  4. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Rabipur. (Last edition: 03.12. 2015). #1880

Similar drugs
Explore alternative drugs in similar therapeutic classes J07B / J07BG or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙